Dishman Carbogen Amcis Ltd. · NSE:DCAL
Dishman Carbogen Amcis — Q1 FY27 Earnings Presentation
24 slides from Dishman Carbogen Amcis's earnings presentation, Aug 17, 2026
Slide 1: Cover letter to stock exchanges
17th August, 2026 To, To, The General Manager The Manager, Department of Corporate Services Listing Department, BSE Ltd. National Stock Exchange of India Ltd. Phiroze Jeejeebhoy Towers, “Exchange Plaza”, C-1, Block G, Dalal Street, Bandra-Kurla Complex, Mumbai – 400 001. Bandra (E), Mumbai – 400 051
Slide 2: Investor Presentation Q1FY27
Investor Presentation Q1FY27 Q uate r ended June 30, 2026
Slide 3: Safe Harbor Statement
This presentation and the following discussion may contain “forward looking statements” by Dishman Carbogen Amcis Limited (‘Dishman’ or the ‘Company’) that are not historical in nature. These forward-looking statements, which may include statements relating to future results of operations, financial
Slide 4: Dishman in a Nutshell
Solving Complex Problems for 23 32 4 250+ Clients Multi-Purpose MANUFACTURING FACILITIES Globally RESEARCH & DEVELOPMENT and HIPO LABS Successful IN-ORGANIC GROWTH TRANSACTIONS DISHMAN IN 4 decades of Long-Standing Track Record in Global Health Authorities Approved & Recognized by CHF 89 M NEW PRODU
Slide 5: Historical Performance at a Glance
Revenue from Operations (₹ mn) EBITDA (₹ mn) and EBITDA % EBITDA EBITDA % 19.3% 17.3% 14.3% 15.5% 13.8% 11.0% 19,120 21,407 24,129 26,158 27,115 29,319 HISTORICAL 2,743 3,314 3,322 2,865 4,690 5,656 Strong basket of 13 molecules in Late Phase III development. PERFORMANCE FY21 FY22 FY23 FY24 FY25 FY
Slide 6: Agenda
AGENDA 01 02 03 Quarter Company Industry Highlights Overview Overview
Slide 7: Quarter Highlights
01 02 03 Quarter Company Industry Highlights Overview Overview
Slide 8: Q1FY27 Result Highlights
NET REVENUE (₹ mn) EBITDA (₹ mn) & EBITDA MARGIN (%) 19.9% 21 . 0% 19 . 0% 17 . 0% 15 . 0% 8.9% 13 . 0% 11 . 0% 9.0% 7.0% 7,081 6,776 1,407 601 5.0% 3.0% 1.0% Q1FY26 Q1FY27 Q1FY26 Q1FY27 Q1FY27 RESULT SEGMENT WISE REVENUE BREAKUP (₹ mn) HIGHLIGHTS 968 1,433 6,113 5,344 Q1FY26 Q1FY27 CDMO Marketable
Slide 9: Consolidated P&L Statement
Particulars (₹ mn) Q1 FY27 Q1 FY26 YoY % Income from Operations (Net) 6,776.4 7,080.5 -4.3% COGS 1,142.3 980.9 16.5% Employee Expenses 3,891.0 3,519.0 10.6% Other Expenses 1,142.3 1,173.8 -2.7% EBITDA 600.8 1,406.8 -57.3% EBIDTA Margin % 8.9% 19.9% CONSOLIDATED Other Income 181.6 247.5 -26.6% Deprec
Slide 10: Revenue Breakup Analysis & Margin Breakup Analysis
Revenue (₹ mn) Q1 FY27 Q1 FY26 FY26 FY25 CDMO 5,343.8 6,112.5 24,412.5 22,930.0 Marketable Molecules 1,432.6 968.0 4,906.5 4,185.0 Total Revenue 6,776.4 7,080.5 29,319.0 27,115.0 Total Operating Revenue – Q1 FY27 Total Operating Revenue – FY26 REVENUE BREAKUP 21% 17% CDMO ANALYSIS & FY26 Q1 FY27 MAR
Slide 11: Q1FY27 Result Highlights
➢ Net revenue stood at ₹6,776 million in Q1 FY27, down 4.29% from ₹7,080 million in Q1 FY26. The decline was primarily driven by deferment of CDMO revenue, partly offset by growth in the Marketable Molecules (MM) segment. ➢ CDMO revenue declined by 12.6% YoY, primarily due to the customer-requested
Slide 12: Company Overview
02 01 03 Company Quarter Industry Overview Highlights Overview
Slide 13: About Us
Established in 1983, Dishman Carbogen Amcis Limited is a fully integrated CDMO (Contract Development and Manufacturing Organisation) company with strong capabilities right from process research & development to late stage clinical and commercial manufacturing and supply of API to innovator pharmaceu
Slide 14: Key Strengths
Global integrated CDMO End-to-end capabilities with bi-continental under one roof — manufacturing footprint spanning pre-clinical KEY for complex, high-value molecules. KEY development, process optimization, scale-up, STRENGTHS STRENGTHS and global commercial manufacturing. Strategic co-investment S
Slide 15: ADC & Bioconjugation Integrated Business at CGAM / DCAL
BIO-CONJUGATION Services DL/BDS/DP GMP-manufacturing Process Transfer/development/validation ICH Stability QC&A Transfer/development/validation End-to-end RA support ADC & Bioconjugation Integrated DL BDS DP Business at Drug Linker* Bulk Drug Substance Drug Product GMP-manufacture GMP-manu
Slide 16: ADC & Bioconjugation Integrated Business at CGAM / DCAL
ADC & Bioconjugation Integrated Client base is from small biotech up to the biggest pharma Business at 30% companies Successful success rate collaboration CGAM / DCAL so far agreements with start-up companies More alliances with potential Dozens of quotes partners under for multiple discussions diff
Slide 17: Manufacturing Facilities and Robust R&D Capabilities
Superior Chemistry Skills & Capabilities Facilities are approved by recognized health agencies: USFDA, MEB, SWISS MEDIC, ANSM, WHO, MFDS, PMDA, NMPA 32 dedicated R&D labs with multiple shift R&D operations, including HIPO labs 25 multi-purpose facilities at CARBOGEN AMCIS BV., Veenendaal, The CARB
Slide 18: One of the Preferred Global Outsourcing Partners
CLOSE PROXIMITY LARGE SCALE INTEGRATED ACROSS STRONG CHEMISTRY TO CLIENTS WITH MANUFACTURING THE VALUE CHAIN CAPABILITIES GLOBAL PRESENCE CAPACITIES ONE OF THE PREFERRED Integrated CDMO Player present along the entire value chain from building blocks to commercialization and product launch stage GLO
Slide 19: Integrated CDMO Player
From Pre-clinical Development To Global Commercial Launch – All Under One Roof Integrated CDMO Player – Strong Capabilities across Value Chain Drug substance & Drug product Pre-clinical Phase I Phase II Phase III Market Early Stage Late Stage Commercial Supply Process Research and API supply to Proc
Slide 20: Industry Overview
03 01 02 Industry Quarter Company Overview Highlights Overview
Slide 21: Top 20 Therapy Areas (US$ bn) - 2029
Oncology & Obesity expected to lead growth 5-Yr CAGR 2024-2029 Oncology 441 11-14% Diabetes 259 6-9% Expected Immunology Cardiovascular 119 234 4-7% 0-3% Top 20 Therapy Areas (US$ bn) - 2029 CNS 109 6-9% Global Respiratory Other endocrine… 96 108 5-8% 5-8% Infectious diseases 80 Oncology continues
Slide 22: Specialty medicines share of spending
Specialty medicines will represent about 46% of global spending in 2029 and 56% of total spending in developed markets 54% 51% 45% 46% Specialty 42% 38% 36% 35% medicines 33% 31% 27% share of 24% 18% spending 11% 14% 8% 2014 2019 2024 2029 Pharmerging Other Developed Global 10 Developed Source: IQVI
Slide 23: June Shareholding Pattern
NSE Ticker DCAL BSE Ticker 540701 June Share Price (₹)^ 175.37 2026 Market Cap (₹ Mn)^ 27,495 % Free Float^ 40.68% Shareholding Free float market cap (₹ Mn)^ 11,184 Pattern Shares outstanding^ 15,67,83,095 PROMOTER 59.32% 3M ADTV (Shares) 5,84,965 DII 2.07% FII 6.86% 3M ADTV (₹ Mn) 111.13 Others 31.
Slide 24: Thank you
Thank you FOR FURTHER QUERIES Arpit Mundra | Krishna Patel Mr. Harshil Dalal Ernst & Young LLP Global CFO Email: [email protected] Email: [email protected] [email protected] Dishman Carbogen Amcis Ltd Dishman Corporate House Iscon-Bopal Road, Ambli Ahmedabad – 380058 Gujarat
Dishman Carbogen Amcis — Q1 FY27 Earnings Presentation on 6ix